Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stevanato (STVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Evan Coleman is an Updates Editor on the Credit Cards and Travel Rewards team at Forbes Advisor, showcasing his interest in personal finance and love of travel. He has written for a variety of local ...

The recent blunder committed by the Joint Admissions and Matriculation Board (JAMB) and perennial whispers around the West African ...

To activate Power Pivot, go to File > Options, click Add-ins, select COM Add-ins from the dropdown, and check the box for ...

Opera Limited ( NASDAQ: OPRA) Citi’s 2025 Global Technology, Media and Telecommunications Conference September 5, 2025 8:50 AM EDT Great. So we're on the clock. So we'll get started here. My name is ...

Business-to-business (B2B) ecommerce is one of the fastest-growing sales models, with more than half of lB2B transactions ...

HackerRank isn’t just a random collection of problems; they’ve organized their SQL section pretty well. You can find ...

To do that, select the Data tab, highlight the table, and click From Table/Range in the Get & Transform Data command group of ...

Penny Gusner is a senior insurance writer and analyst at Forbes Advisor. For more than 20 years, she has been helping consumers learn how insurance laws, data, trends, and coverages affect them. Penny ...

Alternative splicing of hundreds of genes in neurons generates isoforms essential for synaptic plasticity during a critical ...